Biotechnology is a key driver of innovation in the life sciences industry. With advances in immuno-oncology, gene and cell therapies, and microbiome therapeutics as examples, the global biotech industry is expected to hit revenues of over $300B in 2019[1][2]. It is further estimated to reach a market value of $727B by 2025[3]. Globally, there are more than 12,400 biotech businesses employing close to a million people [2]. Business Stimulant , LLC (“BusStim, LLC”) brings an innovative approach to accelerating the drug/product development process in the Biotechnology Industry. BusStim advances assets to key milestone/transition points through translational research strategies to increase asset value and mitigate risk. We accomplish this through a risk-sharing arrangement and utilization of a highly experienced former Big Pharma team. Our approach improves success rates based on our upfront due diligence, cost efficiencies, and strategic as well as operational translational research planning.
Sources: 1.Albert H. 2019. European Biotechnology in 2019 2.IBIS World. 2019. Industry Market Research, Reports, and Statistics. 3.Grand View Research. 2017
Our mission
Partnering with academic institutions and biotechnology companies to provide industry knowledge and proven expertise — thereby enabling them to de-risk their product, increase its value, and ultimately achieve long-term financial success via a Pharma deal.
My inspiration
Contact us to start improving your biotech business
Follow us
